PGHL Q3 Results: Sales Surge 21% to ₹368 Crore; Interim Dividend of ₹160 Declared
Procter & Gamble Health Ltd. reported Q3 FY26 sales of ₹368 crore, a 21% increase year-over-year. Profit After Tax (PAT) was ₹78 crore. The company declared an interim dividend of ₹160 per equity share for FY26, including a special dividend of ₹50.
The significant sales growth and the declaration of a substantial interim dividend, including a special one, are likely to be viewed positively by investors and impact the company's stock.
The company reported strong sales growth and declared a substantial interim dividend, indicating positive financial performance and shareholder returns.
Procter & Gamble Health Limited (PGHL) announced its unaudited financial results for the third quarter ended December 31, 2025. The company reported a significant sales increase of 21% year-on-year, reaching ₹368 crore. This growth was attributed to strong brand fundamentals and positive consumer reception to new innovations.
Profit After Tax (PAT) for the quarter stood at ₹78 crore. Milind Thatte, Managing Director, P&G Health, highlighted the company's strategic efforts, including new innovations like Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream, and enhanced supply chain capabilities, as drivers for the strong top-line growth.
He further emphasized the company's commitment to addressing consumer needs through superior brand building, go-to-market initiatives, and science-backed innovations, aiming to help consumers live healthier lives. The company also declared an interim dividend of ₹160 per equity share for the financial year 2025-26, which includes a one-time special dividend of ₹50 per share.
What to do with a filing like this
Procter & Gamble Health Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Procter & Gamble Health Limited. Read the original for the full detail.